Upside – $CNTB +83% (Phase 2 COPD trial met its primary endpoint, reducing treatment failures by 81% and new moderate-to-severe exacerbations by 85%) – $NAUT +16% (no clear fresh catalyst identified; unusually large, liquid premarket move) – $CAPR +14% (new deramiocel analyses showed slower upper-limb decline in the HOPE-3 open-label extension and versus natural history) …
Read in context ›Nautilus Biotechnolgy Stock (NAUT)
Track Nautilus Biotechnolgy stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
NAUT
Nautilus Biotechnolgy
healthcare
At close
$2.25
â–² +0.43 (+23.63%)
Oct 9, 4:00 PM ET
After-hours
$2.25
• +0.00 (0.00%)
Oct 9, 7:59 PM ET
Market Cap
$231.60M
P/E Ratio
—
1Y Return
+150.00%
EPS (TTM)
-$0.45
Read the latest TheStreet Pro articles mentioning Nautilus Biotechnolgy, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning NAUT yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning